Biopharmaceutical company Vaccitech has taken 31,000 sq ft at the Zeus building at the Harwell Campus.

The letting accounts for around half the new building which is one of a number in the latest development phase of Harwell.

Vaccitech chief operating officer Chris Ellis said: “Vaccitech has a broad pipeline of programmes in clinical trials and manufacturing for a biotechnology company of its size.

“This reflects the ambition, passion and drive that is felt right across the company and its investors as we strive to bring new immunotherapeutics and vaccines to the world.

“The need for new space designed primarily for state-of-the-art wet laboratory and offices to house our growing team was our first priority and, staying within the Oxfordshire infrastructure drove our decision to relocate to the Zeus building at Harwell Campus.”

Harwell Campus chief executive Stuart Grant said: “I’m delighted that Vaccitech has chosen the campus as its base to grow the business and to develop future vaccine manufacturing capability.

“We have an in-depth understanding of the needs of our diverse customer base, which allows us to provide the right environment and tailored space to retain talent and expertise, attract investment into the UK life sciences sector and help the Government cement the UK’s position as a global science superpower.”

© Thames Tap (powered by

Sign up to receive your free weekly Thames Tap newsletter here.